CN108686119A - 一种治疗痛风的药物组合物及其应用 - Google Patents
一种治疗痛风的药物组合物及其应用 Download PDFInfo
- Publication number
- CN108686119A CN108686119A CN201810682148.6A CN201810682148A CN108686119A CN 108686119 A CN108686119 A CN 108686119A CN 201810682148 A CN201810682148 A CN 201810682148A CN 108686119 A CN108686119 A CN 108686119A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- frankincense
- curcumin
- lemon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
- 201000005569 Gout Diseases 0.000 title claims abstract description 25
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 36
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 36
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 19
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 19
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 19
- 240000004784 Cymbopogon citratus Species 0.000 claims abstract description 19
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims abstract description 19
- 239000004863 Frankincense Substances 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 19
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 18
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000012754 curcumin Nutrition 0.000 claims abstract description 18
- 229940109262 curcumin Drugs 0.000 claims abstract description 18
- 239000004148 curcumin Substances 0.000 claims abstract description 18
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 18
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000005875 quercetin Nutrition 0.000 claims abstract description 18
- 229960001285 quercetin Drugs 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 239000002552 dosage form Substances 0.000 claims description 9
- -1 oral solution Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 claims 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 claims 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 claims 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 claims 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 claims 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 239000000203 mixture Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 2
- 229960002708 antigout preparations Drugs 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 8
- 229940116269 uric acid Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 3
- 244000163122 Curcuma domestica Species 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940043350 citral Drugs 0.000 description 3
- 235000003373 curcuma longa Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗痛风的药物组合物及其应用，该组合物含有下列重量份的药物：姜黄素500‑3000份、槲皮素200‑3000份、香茅草提取物500‑3000份以及乳香1000‑5000份。该药物组合物具有优异的抗痛风效果，可用于制备治疗或预防痛风性关节炎和/或高尿酸血症的药物、保健品或食品。该药物组合物副作用少、成本低、制备方法简单、易于工业化应用。
Description
技术领域
本发明属于制药领域，涉及一种治疗痛风的药物组合物及其应用
背景技术
我国高尿酸血症患者人数已达1.7亿，其中痛风患者超过8000万人，而且正以每年9.7％的年增长率迅速增加。预计2020年，痛风人数将达到1亿。现今痛风已经成为我国仅次于糖尿病的第二大代谢类疾病，是不可忽视的健康警示。痛风的危害不仅在于关节损伤，后期的相关并发症(心脑血管疾病、肝肾功能障碍)是导致痛风患者死亡的主要原因。
痛风是一种体内尿酸代谢紊乱，导致关节沉积尿酸结晶的一种关节病，具有多并发症、病程长、发作剧烈等特点，西方医学认为痛风目前无法治愈。本发明人根据多年的临床经验认为痛风与压力应激因素、氧化因素、食物过敏因素、滥用抗生素和止痛药、肝脏解毒功能低下等导致的细胞氧化受损有关，导致产生炎性反应从而引起尿酸代谢异常。
随着对痛风发病机理深入的研究、以及目前发现一线治疗痛风的药物对肝肾损伤的案例越来越多，越来越多的学者认同痛风发病是多因素致病，不能用单一因素干预痛风。为此，本发明提出利用多靶点治疗的方式开发治疗痛风的药物。
发明内容
本发明的一个目的是提供一种通过多靶点干预来有效治疗或预防痛风、缓解疼痛、抑制尿酸增高、恢复和改善患者代谢功能且无毒副作用的用于预防和治疗痛风性关节炎和/或高尿酸血症的药物组合物。
本发明的另一个目的是提供上述组合物在制备治疗或预防痛风性关节炎和/或高尿酸血症的药物、保健品或食品中的应用。
本发明的目的是通过下列技术方案实现的：
本发明提供一种治疗痛风的药物组合物，包括乳香、姜黄素、槲皮素和香茅草提取物。
优选地，所述药物组合物包括以下重量份的药物：乳香1000-5000份、姜黄素500-3000份、槲皮素200-3000份和香茅草提取物500-3000份。
更优选地，所述药物组合物包括以下重量份的药物：乳香2000-5000份、姜黄素1500-3000份、槲皮素1500-3000份和香茅草提取物1500-3000份。
最优选地，所述药物组合物包括以下重量份的药物：乳香3000份、姜黄素1500份、槲皮素1500份、香茅草提取物1500份。
所述组合物的剂型为药学或保健品允许的任意剂型，优选选自片剂、胶囊剂、颗粒剂、粉剂、丸剂、口服液、注射剂和膜剂。
所述组合物在制备治疗或预防痛风性关节炎和/或高尿酸血症的药物、保健品或食品中的应用。
乳香是一种含挥发油的胶质树脂，具有活血行气、通经止痛、消肿生肌的作用。乳香中的乙酸正辛酯是发挥止疼作用的主要物质，同时乳香能促进多核白细胞的增加，以吞噬死亡的细胞，改善新陈代谢，从而起到消炎止疼的作用，能很好的消除痛风的疼痛作用，此药为君药。
姜黄是姜科植物的根茎，在印度及亚洲曾被应用超过6000年以上的历史。姜黄素是姜黄的有效成分，姜黄素可以抑制炎性反应、抗氧化、抗类风湿、降脂的作用。
槲皮素是一种植物来源的类黄酮，广泛分布于蔬菜、水果、干果以及中草药中，经临床证明槲皮素具有抗氧化、抗炎、减少循环障碍等。槲皮素能增强谷胱甘肽-S-转移酶、超氧化物歧化酶等的活性，促进肝脏的解毒代谢和排出功能。有效的捕获和清除氧自由基防止或减轻氧自由基增加抗氧化功能，减少组织细胞的氧化能力，从而增加细胞对尿酸的代谢能力来降低痛风的发生。
香茅草提取物是由香茅草中提取，属于植物次生代谢物质，主要由柠檬醛、香叶醇、香叶烯、乙酸香叶酮等成分构成，具有祛风除湿，消肿止痛的功效。香茅草中的柠檬醛有治疗神经痛、肌肉痛、风湿痛的效果，因而被誉为“消痛剑客”美誉。
本发明创造性地将乳香、姜黄素、槲皮素、香茅草提取物进行组合，形成一类新的具有治疗痛风作用的组合物。本发明人出乎意料地发现上述四种具有不同作用靶点的成分之间具有相互协同的治疗痛风性关节炎和高尿酸血症的效果，其疗效远优于上述组分中的任意单独一种的疗效。该药物组合物在临床试验中也具有较好的治疗痛风的作用且安全可靠、成本低、原料易得，易于推广应用。
制备该药物组合物的原料均可用于保健品或食品，副作用少，原料来源广泛，制备方法简单易行，便于工业化生产。
具体实施方案
下面结合具体实施例来描述本发明，应该指出的是，这些实施例仅用于说明本发明而不应理解为对本发明的限制。
任何不采取组合物的形式但分别取各原料依据本发明记载的用量共同作用于治疗痛风或高尿酸血症的情形也属于本发明保护的内容。
乳香中的乙酸正辛酯是发挥止疼作用的主要物质，同时乳香能促进多核白细胞的增加，以吞噬死亡的细胞，改善新陈代谢、从而起到消炎止疼的作用，能很好的消除痛风的疼痛作用，此药为君药。姜黄素是姜黄的有效成分，姜黄素可以抑制炎性反应、抗氧化、抗类风湿、降脂的作用。槲皮素具有抗氧化、抗炎、减少循环障碍等功效。香茅草中的柠檬醛有治疗神经痛、肌肉痛、风湿痛的效果。诸药配伍独特、合用科学。
可以通过本领域的常规制备方法，将发明的药物组合物制成任何一种临床上适合的剂型，例如丸剂、片剂、胶囊、颗粒剂、口服液等。本发明所提供的用于预防和治疗痛风性关节炎及高尿酸的药物组合物的剂型可以是药学上允许且人体能够接受的任意剂型，并不局限于本发明所列举的。根据剂型的不同，本发明的药物组合物的加工方法也可以有区别。
临床验证试验：
按照以下方法进行多组针对性试验：
本发明的药物组合物用水煎服，每日三次，一个月为一个疗程。服用三个疗程。
疗效观察
疗效标准：参照《中医病症诊断疗效标准》
痊愈：症状消失，血尿酸检查正常。
好转：关节肿胀减退，疼痛缓解，实验室检查有改善(血尿酸下降超过30％)。
无效：症状以及实验室检查无变化(血尿酸下降不超过30％)。
实施例一
选取药物组合物的配方为乳香1000份、姜黄素500份、槲皮素200份、香茅草提取物3000份。取上药用水煎服，每日3次，疗程3个月。经过数年临床对201例患者进行治疗和观察，其中痊愈156例，痊愈率77.6％；显效21例，显效率10.4％；总有效率88％。
实施例二
选取药物组合物的配方为乳香5000份、姜黄素3000份、槲皮素3000份、香茅草提取物3000份。取上药用水煎服，每日3次，疗程3个月。经过数年临床对201例患者进行治疗和观察，其中痊愈164例，痊愈率81.5％；显效25例，显效率12.4％；总有效率93.9％。
实施例三
选取药物组合物的配方为乳香3000份、姜黄素1500份、槲皮素1500份、香茅草提取物1500份。取上药用水煎服，每日3次，疗程3个月。经过数年来临床对201例患者进行治疗和观察，其中痊愈173例，痊愈率86.0％；显效27例，显效率13.4％；总有效率98％。
依据临床观察，实施例三的配方：乳香3000份、姜黄素1500份、槲皮素1500份、香茅草提取物1500份，效果最佳，痊愈率达86.0％。
本实施例的产品原料乳香、姜黄素、槲皮素和香茅草提取物均购自陕西森弗集团公司。
所属领域的普通技术人员应当理解：以上任何实施例的讨论仅为示例性的，并非旨在暗示本公开的范围限于这些例子。本发明的实施例旨在涵盖落入所附权利要求的宽泛范围之内的所有这样的替换、修改和变型。因此，凡在本发明的精神和原则之内，所做的任何省略、修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (7)
1.一种治疗痛风的药物组合物，其特征在于，所述药物组合物包括乳香、姜黄素、槲皮素以及香茅草提取物。
2.如权利要求1所述的药物组合物，其特征在于，所述药物组合物包括下列重量份的药物：乳香1000-5000份、姜黄素500-3000份、槲皮素200-3000份以及香茅草提取物500-3000份。
3.如权利要求1所述的药物组合物，其特征在于，所述药物组合物包括下列重量份的药物：乳香2000-5000份、姜黄素1500-3000份、槲皮素1500-3000份和香茅草提取物1500-3000份。
4.如权利要求1所述的药物组合物，其特征在于，所述药物组合物包括下列重量份的药物：乳香3000份、姜黄素1500份、槲皮素1500份和香茅草提取物1500份。
5.如权利要求1所述的药物组合物，其特征在于，所述药物组合物的剂型为药学上允许的任意剂型。
6.如权利要求5所述的药物组合物，其特征在于，所述剂型选自片剂、胶囊剂、颗粒剂、粉剂、丸剂、口服液、注射剂和膜剂中的任意一种。
7.如权利要求1-6中任一项所述的药物组合物在制备治疗和预防痛风性关节炎和/或高尿酸血症的药物、保健品或食品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810682148.6A CN108686119A (zh) | 2018-06-27 | 2018-06-27 | 一种治疗痛风的药物组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810682148.6A CN108686119A (zh) | 2018-06-27 | 2018-06-27 | 一种治疗痛风的药物组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108686119A true CN108686119A (zh) | 2018-10-23 |
Family
ID=63850120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810682148.6A Pending CN108686119A (zh) | 2018-06-27 | 2018-06-27 | 一种治疗痛风的药物组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108686119A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110384770A (zh) * | 2018-04-16 | 2019-10-29 | 文小燕 | 用于治疗痛风的柠檬草提取物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105246499A (zh) * | 2013-05-29 | 2016-01-13 | 雀巢产品技术援助有限公司 | 用于软骨破坏的组合物 |
| CN105263505A (zh) * | 2013-05-29 | 2016-01-20 | 雀巢产品技术援助有限公司 | 用于软骨破坏的组合物 |
| US20160263139A1 (en) * | 2013-10-14 | 2016-09-15 | Nestec S.A. | Anti-inflammatory phytonutrients for use in the treatment or prevention of synovitis |
-
2018
- 2018-06-27 CN CN201810682148.6A patent/CN108686119A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105246499A (zh) * | 2013-05-29 | 2016-01-13 | 雀巢产品技术援助有限公司 | 用于软骨破坏的组合物 |
| CN105263505A (zh) * | 2013-05-29 | 2016-01-20 | 雀巢产品技术援助有限公司 | 用于软骨破坏的组合物 |
| US20160263139A1 (en) * | 2013-10-14 | 2016-09-15 | Nestec S.A. | Anti-inflammatory phytonutrients for use in the treatment or prevention of synovitis |
Non-Patent Citations (1)
| Title |
|---|
| 孙磊，等: "乳香基原的本草学、植物学和成分分析研究", 《中国中药杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110384770A (zh) * | 2018-04-16 | 2019-10-29 | 文小燕 | 用于治疗痛风的柠檬草提取物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005110431A1 (en) | Herbal product containing glucosamine | |
| CN109674958A (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
| Ganji-Arjenaki et al. | Phytotherapies in inflammatory bowel disease | |
| Hu et al. | Antidiarrhoeal and intestinal modulatory activities of Wei-Chang-An-Wan extract | |
| CN102188513A (zh) | 对化学性肝损伤具有辅助保护功能的药物组合物 | |
| Panossian et al. | Efficacy of Andrographis paniculata in upper respiratory tract infectious diseases and the mechanism of action | |
| Wu et al. | Application of traditional Chinese medicines in postoperative abdominal adhesion | |
| Sieniawska et al. | Plant‐based food products for antimycobacterial therapy | |
| CN101143202B (zh) | 一种对化学性肝损伤具有保护作用的复方口服制剂 | |
| JP6121556B2 (ja) | ハーブサプリメントおよびその使用の方法 | |
| CN104740425B (zh) | 一种治疗风湿痹症的药物组合物及其制备方法和用途 | |
| Singh et al. | Principles of Rajayakshma management for COVID-19 | |
| KR102018221B1 (ko) | 보스웰리아 추출물, 포도씨 추출물, 강황 추출물, 녹차 추출물, 생강 추출물 및 백미 추출물을 유효성분으로 함유하는 관절염의 예방, 개선 또는 치료용 조성물 | |
| Alburyhi et al. | Formulation, Development and Evaluation of Tribulus Terrestris Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Controlling Diabetes | |
| KR101987418B1 (ko) | 혼합 생약 추출물을 유효성분으로 함유하는 뇌신경 보호용 조성물 | |
| CN108686119A (zh) | 一种治疗痛风的药物组合物及其应用 | |
| CN104435977B (zh) | 一种用于治疗肝损伤的药物及其制备方法 | |
| CN109925445A (zh) | 金线莲提取物在制备预防和/或治疗d-氨基半乳糖致小鼠急性肝损伤药物中的应用 | |
| CN109172663B (zh) | 一种治疗焦虑抑郁的药物组合物及其应用 | |
| CN103251789B (zh) | 治疗猪瘟的中药剂 | |
| CN102836354B (zh) | 一种治疗抑郁症的药剂 | |
| CN102599501B (zh) | 降脂护肝的保健食品红洋胶囊或片剂 | |
| Kumar et al. | Assessment of hepatoprotective and nephroprotective effects of Vitis vinifera leaf extract on carbon tetrachloride induced toxicity in rats | |
| CN107617018A (zh) | 一种用于治疗家畜疱疹性皮炎的药物组合物及其应用方法 | |
| CN103877297A (zh) | 一种治疗小儿疝气的药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |